MedTrace Logo

Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure

NCT04318093 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-08-04

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

BMS-986259

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2021-07-19
Completion
2021-07-19
FDA Drug
Yes

Countries

  • Argentina
  • Czechia
  • Greece
  • Israel
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318093 on ClinicalTrials.gov